Literature DB >> 20888974

Cabazitaxel in prostate cancer: stretching a string.

Tanya B Dorff1, David I Quinn.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20888974     DOI: 10.1016/S0140-6736(10)61510-3

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  4 in total

1.  Cabazitaxel: filling one of the gaps in the treatment of prostate cancer.

Authors:  William D Figg; William D Figg
Journal:  Cancer Biol Ther       Date:  2010-12-15       Impact factor: 4.742

2.  Optimal management of patients receiving cabazitaxel-based chemotherapy.

Authors:  Catherine Sperlich; Fred Saad
Journal:  Can Urol Assoc J       Date:  2013 Jan-Feb       Impact factor: 1.862

3.  Chemotherapy for prostate cancer: Clinical practice in Canada.

Authors:  Fred Saad; Jamil Asselah
Journal:  Can Urol Assoc J       Date:  2013 Jan-Feb       Impact factor: 1.862

4.  Inhibiting the NF-κB pathway enhances the antitumor effect of cabazitaxel by downregulating Bcl-2 in pancreatic cancer.

Authors:  Zequn Li; Zefeng Xuan; Jian Chen; Wenfeng Song; Shiyu Zhang; Cheng Jin; Mengqiao Zhou; Shusen Zheng; Penghong Song
Journal:  Int J Oncol       Date:  2020-04-27       Impact factor: 5.650

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.